$PCRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Pacira BioSciences, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Pacira BioSciences, Inc.. Get notifications about new insider transactions in Pacira BioSciences, Inc. for free.
Page: < prev 1 2 3 4 5 6 7 ... 9 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 13 2019 | PCRX | Pacira BioSciences ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 1.61 | 15,000 | 24,150 | 44,000 | |
Jun 13 2019 | PCRX | Pacira BioSciences ... | STACK DAVID M | CEO and Chairman | Buy | M | 5.49 | 9,000 | 49,410 | 169,231 | 160.2 K to 169.2 K (+5.62 %) |
Jun 13 2019 | PCRX | Pacira BioSciences ... | STACK DAVID M | CEO and Chairman | Buy | M | 1.61 | 15,000 | 24,150 | 160,231 | 145.2 K to 160.2 K (+10.33 %) |
Jun 12 2019 | PCRX | Pacira BioSciences ... | Riker Lauren Bullaro | Vice President, Fin ... | Sell | S | 44.28 | 2,126 | 94,139 | 10,042 | 12.2 K to 10 K (-17.47 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | WINSTON ROY | Chief Clinical Offi ... | Option Exercise | A | 43.54 | 33,800 | 1,471,652 | 33,800 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | WINSTON ROY | Chief Clinical Offi ... | Grant | A | 0.00 | 5,600 | 0 | 22,139 | 16.5 K to 22.1 K (+33.86 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | WINSTON ROY | Chief Clinical Offi ... | Sell | S | 42.91 | 722 | 30,981 | 16,539 | 17.3 K to 16.5 K (-4.18 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Williams Kristen Marie | CAO and General Cou ... | Option Exercise | A | 43.54 | 33,800 | 1,471,652 | 33,800 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Williams Kristen Marie | CAO and General Cou ... | Grant | A | 0.00 | 5,600 | 0 | 25,445 | 19.8 K to 25.4 K (+28.22 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Williams Kristen Marie | CAO and General Cou ... | Sell | S | 42.91 | 2,529 | 108,519 | 19,845 | 22.4 K to 19.8 K (-11.30 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | STACK DAVID M | CEO and Chairman | Option Exercise | A | 43.54 | 142,100 | 6,187,034 | 142,100 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | STACK DAVID M | CEO and Chairman | Grant | A | 0.00 | 23,700 | 0 | 145,231 | 121.5 K to 145.2 K (+19.50 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | STACK DAVID M | CEO and Chairman | Sell | S | 42.91 | 12,385 | 531,440 | 121,531 | 133.9 K to 121.5 K (-9.25 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Option Exercise | A | 43.54 | 30,000 | 1,306,200 | 30,000 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Grant | A | 0.00 | 5,000 | 0 | 16,061 | 11.1 K to 16.1 K (+45.20 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Sell | S | 43.50 | 4,114 | 178,959 | 11,061 | 15.2 K to 11.1 K (-27.11 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Sell | S | 42.66 | 2,852 | 121,666 | 15,175 | 18 K to 15.2 K (-15.82 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Sell | S | 42.91 | 2,074 | 88,995 | 18,027 | 20.1 K to 18 K (-10.32 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Riker Lauren Bullaro | Vice President, Fin ... | Option Exercise | A | 43.54 | 11,200 | 487,648 | 11,200 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Riker Lauren Bullaro | Vice President, Fin ... | Grant | A | 0.00 | 1,900 | 0 | 12,168 | 10.3 K to 12.2 K (+18.50 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Riker Lauren Bullaro | Vice President, Fin ... | Sell | S | 42.91 | 967 | 41,494 | 10,268 | 11.2 K to 10.3 K (-8.61 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Reinhart Charles A. III | Chief Financial Off ... | Option Exercise | A | 43.54 | 26,300 | 1,145,102 | 26,300 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Reinhart Charles A. III | Chief Financial Off ... | Grant | A | 0.00 | 4,400 | 0 | 16,336 | 11.9 K to 16.3 K (+36.86 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Reinhart Charles A. III | Chief Financial Off ... | Sell | S | 42.91 | 1,106 | 47,458 | 11,936 | 13 K to 11.9 K (-8.48 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | PACE GARY W | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | PACE GARY W | Director | Grant | A | 0.00 | 4,134 | 0 | 36,953 | 32.8 K to 37 K (+12.60 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | McLoughlin Dennis | Chief Commercial Of ... | Option Exercise | A | 43.54 | 33,800 | 1,471,652 | 33,800 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | McLoughlin Dennis | Chief Commercial Of ... | Grant | A | 0.00 | 5,600 | 0 | 19,422 | 13.8 K to 19.4 K (+40.52 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | McLoughlin Dennis | Chief Commercial Of ... | Sell | S | 42.91 | 1,099 | 47,158 | 13,822 | 14.9 K to 13.8 K (-7.37 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LONGENECKER JOHN P PHD | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LONGENECKER JOHN P PHD | Director | Grant | A | 0.00 | 4,134 | 0 | 10,061 | 5.9 K to 10.1 K (+69.75 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Option Exercise | A | 43.54 | 30,000 | 1,306,200 | 30,000 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Grant | A | 0.00 | 5,000 | 0 | 10,367 | 5.4 K to 10.4 K (+93.16 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Sell | S | 42.91 | 430 | 18,451 | 5,367 | 5.8 K to 5.4 K (-7.42 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Kronenfeld Mark A. | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Kronenfeld Mark A. | Director | Grant | A | 0.00 | 4,134 | 0 | 14,411 | 10.3 K to 14.4 K (+40.23 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 4,134 | 0 | 6,881 | 2.7 K to 6.9 K (+150.49 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Sell | S | 42.66 | 782 | 33,360 | 2,747 | 3.5 K to 2.7 K (-22.16 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Greenstreet Yvonne | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Greenstreet Yvonne | Director | Grant | A | 0.00 | 4,134 | 0 | 9,761 | 5.6 K to 9.8 K (+73.47 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | PACE GARY W | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | PACE GARY W | Director | Grant | A | 0.00 | 4,134 | 0 | 36,953 | 32.8 K to 37 K (+12.60 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | McLoughlin Dennis | Chief Commercial Of ... | Option Exercise | A | 43.54 | 33,800 | 1,471,652 | 33,800 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | McLoughlin Dennis | Chief Commercial Of ... | Grant | A | 0.00 | 5,600 | 0 | 19,422 | 13.8 K to 19.4 K (+40.52 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | McLoughlin Dennis | Chief Commercial Of ... | Sell | S | 42.91 | 1,099 | 47,158 | 13,822 | 14.9 K to 13.8 K (-7.37 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LONGENECKER JOHN P PHD | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LONGENECKER JOHN P PHD | Director | Grant | A | 0.00 | 4,134 | 0 | 10,061 | 5.9 K to 10.1 K (+69.75 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Option Exercise | A | 43.54 | 30,000 | 1,306,200 | 30,000 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Grant | A | 0.00 | 5,000 | 0 | 10,367 | 5.4 K to 10.4 K (+93.16 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Sell | S | 42.91 | 430 | 18,451 | 5,367 | 5.8 K to 5.4 K (-7.42 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Kronenfeld Mark A. | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Kronenfeld Mark A. | Director | Grant | A | 0.00 | 4,134 | 0 | 14,411 | 10.3 K to 14.4 K (+40.23 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 4,134 | 0 | 6,881 | 2.7 K to 6.9 K (+150.49 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Sell | S | 42.66 | 782 | 33,360 | 2,747 | 3.5 K to 2.7 K (-22.16 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Greenstreet Yvonne | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Greenstreet Yvonne | Director | Grant | A | 0.00 | 4,134 | 0 | 9,761 | 5.6 K to 9.8 K (+73.47 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Froimson Mark | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Froimson Mark | Director | Grant | A | 0.00 | 4,134 | 0 | 5,016 | 882 to 5 K (+468.71 %) |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Brege Laura | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
Jun 06 2019 | PCRX | Pacira BioSciences ... | Brege Laura | Director | Grant | A | 0.00 | 4,134 | 0 | 8,761 | 4.6 K to 8.8 K (+89.35 %) |
Jun 05 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Option Exercise | M | 10.81 | 12,500 | 135,125 | 0 | |
Jun 05 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Option Exercise | M | 10.52 | 3,010 | 31,665 | 0 | |
Jun 05 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Sell | S | 43.21 | 15,510 | 670,187 | 20,101 | 35.6 K to 20.1 K (-43.55 %) |
Jun 05 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Buy | M | 10.81 | 12,500 | 135,125 | 35,611 | 23.1 K to 35.6 K (+54.09 %) |
Jun 05 2019 | PCRX | Pacira BioSciences ... | Scranton Richard | Chief Scientific Of ... | Buy | M | 10.52 | 3,010 | 31,665 | 23,111 | 20.1 K to 23.1 K (+14.97 %) |
Mar 08 2019 | PCRX | Pacira Pharmaceuti ... | Kronenfeld Mark A. | Director | Buy | P | 39.14 | 1,000 | 39,140 | 10,277 | 9.3 K to 10.3 K (+10.78 %) |
Mar 08 2019 | PCRX | Pacira Pharmaceuti ... | Kronenfeld Mark A. | Director | Buy | P | 38.72 | 700 | 27,104 | 9,277 | 8.6 K to 9.3 K (+8.16 %) |
Dec 20 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 5.49 | 6,000 | 32,940 | 51,856 | |
Dec 20 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 1.61 | 6,000 | 9,660 | 59,000 | |
Dec 20 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 5.49 | 6,000 | 32,940 | 133,683 | 127.7 K to 133.7 K (+4.70 %) |
Dec 20 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 1.61 | 6,000 | 9,660 | 127,683 | 121.7 K to 127.7 K (+4.93 %) |
Dec 14 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 46.18 | 8,720 | 402,692 | 950,362 | 959.1 K to 950.4 K (-0.91 %) |
Dec 14 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 47.84 | 5,807 | 277,803 | 959,082 | 964.9 K to 959.1 K (-0.60 %) |
Nov 21 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 47.08 | 990 | 46,605 | 964,889 | 965.9 K to 964.9 K (-0.10 %) |
Nov 21 2018 | PCRX | Pacira Pharmaceuti ... | PACE GARY W | Director | Buy | P | 46.18 | 4,500 | 207,810 | 32,819 | 28.3 K to 32.8 K (+15.89 %) |
Nov 19 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 47.07 | 3,500 | 164,734 | 965,879 | 969.4 K to 965.9 K (-0.36 %) |
Nov 19 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 46.79 | 22,100 | 1,034,041 | 969,379 | 991.5 K to 969.4 K (-2.23 %) |
Nov 19 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 47.64 | 18,809 | 896,145 | 991,479 | 1 M to 991.5 K (-1.86 %) |
Nov 19 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 47.63 | 26,089 | 1,242,666 | 1,010,288 | 1 M to 1 M (-2.52 %) |
Nov 19 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 47.70 | 4,558 | 217,417 | 121,683 | 126.2 K to 121.7 K (-3.61 %) |
Nov 19 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 47.25 | 10,442 | 493,385 | 126,241 | 136.7 K to 126.2 K (-7.64 %) |
Nov 13 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 50.23 | 906 | 45,508 | 1,041,855 | 1 M to 1 M (-0.09 %) |
Nov 13 2018 | PCRX | Pacira Pharmaceuti ... | Wicki Andreas | Director | Sell | S | 51.13 | 57,339 | 2,931,583 | 1,042,761 | 1.1 M to 1 M (-5.21 %) |
Nov 09 2018 | PCRX | Pacira Pharmaceuti ... | PACE GARY W | Director | Buy | P | 51.29 | 4,000 | 205,160 | 28,319 | 24.3 K to 28.3 K (+16.45 %) |
Nov 06 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Option Exercise | M | 10.34 | 1,000 | 10,340 | 23,000 | |
Nov 06 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Sell | S | 54.35 | 1,000 | 54,350 | 10,474 | 11.5 K to 10.5 K (-8.72 %) |
Nov 06 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Buy | M | 10.34 | 1,000 | 10,340 | 11,474 | 10.5 K to 11.5 K (+9.55 %) |
Oct 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 5.49 | 15,000 | 82,350 | 57,856 | |
Oct 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 1.61 | 18,190 | 29,286 | 65,000 | |
Oct 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 1.61 | 11,810 | 19,014 | 0 | |
Oct 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 5.49 | 15,000 | 82,350 | 136,683 | 121.7 K to 136.7 K (+12.33 %) |
Oct 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 1.61 | 18,190 | 29,286 | 121,683 | 103.5 K to 121.7 K (+17.58 %) |
Oct 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 1.61 | 11,810 | 19,014 | 103,493 | 91.7 K to 103.5 K (+12.88 %) |
Sep 26 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Option Exercise | M | 10.34 | 1,000 | 10,340 | 24,000 | |
Sep 26 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Sell | S | 50.70 | 1,000 | 50,700 | 10,474 | 11.5 K to 10.5 K (-8.72 %) |
Sep 26 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Buy | M | 10.34 | 1,000 | 10,340 | 11,474 | 10.5 K to 11.5 K (+9.55 %) |
Sep 07 2018 | PCRX | Pacira Pharmaceuti ... | McLoughlin Dennis | Chief Commercial Of ... | Option Exercise | M | 46.55 | 20,000 | 931,000 | 20,000 | |
Aug 30 2018 | PCRX | Pacira Pharmaceuti ... | Kronenfeld Mark A. | Director | Buy | P | 44.61 | 1,000 | 44,611 | 8,577 | 7.6 K to 8.6 K (+13.20 %) |
Aug 24 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Sell | S | 44.48 | 1,667 | 74,148 | 10,474 | 12.1 K to 10.5 K (-13.73 %) |
Aug 16 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 10.81 | 13,481 | 145,730 | 0 | |
Aug 16 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 5.49 | 610 | 3,349 | 0 | |
Aug 16 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 47.69 | 11,864 | 565,794 | 91,683 | 103.5 K to 91.7 K (-11.46 %) |
Aug 16 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 47.11 | 21,198 | 998,638 | 103,547 | 124.7 K to 103.5 K (-16.99 %) |
Aug 16 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 10.81 | 13,481 | 145,730 | 124,745 | 111.3 K to 124.7 K (+12.12 %) |
Aug 16 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 5.49 | 610 | 3,349 | 111,264 | 110.7 K to 111.3 K (+0.55 %) |
Aug 16 2018 | PCRX | Pacira Pharmaceuti ... | Williams Kristen Marie | CAO and General Cou ... | Sell | S | 47.04 | 4,773 | 224,522 | 22,374 | 27.1 K to 22.4 K (-17.58 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Option Exercise | A | 38.35 | 25,000 | 958,750 | 25,000 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Grant | A | 0.00 | 2,500 | 0 | 12,141 | 9.6 K to 12.1 K (+25.93 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Reinhart Charles A. III | Chief Financial Off ... | Option Exercise | A | 38.35 | 30,000 | 1,150,500 | 30,000 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Reinhart Charles A. III | Chief Financial Off ... | Grant | A | 0.00 | 5,000 | 0 | 13,042 | 8 K to 13 K (+62.17 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Option Exercise | A | 38.35 | 30,000 | 1,150,500 | 30,000 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | LARANJEIRA CHARLES ANTHONY | SVP, Technical Oper ... | Grant | A | 0.00 | 5,000 | 0 | 5,238 | 238 to 5.2 K (+2,100.84 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | PACE GARY W | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | PACE GARY W | Director | Grant | A | 0.00 | 782 | 0 | 24,319 | 23.5 K to 24.3 K (+3.32 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | LONGENECKER JOHN P PHD | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | LONGENECKER JOHN P PHD | Director | Grant | A | 0.00 | 782 | 0 | 5,927 | 5.1 K to 5.9 K (+15.20 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Kronenfeld Mark A. | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Kronenfeld Mark A. | Director | Grant | A | 0.00 | 782 | 0 | 7,577 | 6.8 K to 7.6 K (+11.51 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 782 | 0 | 3,529 | 2.7 K to 3.5 K (+28.47 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Greenstreet Yvonne | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Greenstreet Yvonne | Director | Grant | A | 0.00 | 782 | 0 | 5,627 | 4.8 K to 5.6 K (+16.14 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Froimson Mark | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Froimson Mark | Director | Grant | A | 0.00 | 782 | 0 | 882 | 100 to 882 (+782.00 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Grant | A | 0.00 | 782 | 0 | 4,627 | 3.8 K to 4.6 K (+20.34 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Williams Kristen Marie | CAO and General Cou ... | Option Exercise | A | 38.35 | 47,250 | 1,812,038 | 47,250 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Williams Kristen Marie | CAO and General Cou ... | Grant | A | 0.00 | 7,875 | 0 | 27,147 | 19.3 K to 27.1 K (+40.86 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | A | 38.35 | 170,250 | 6,529,088 | 170,250 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Grant | A | 0.00 | 28,375 | 0 | 110,415 | 82 K to 110.4 K (+34.59 %) |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Scranton Richard | Chief Scientific Of ... | Option Exercise | A | 38.35 | 47,250 | 1,812,038 | 47,250 | |
Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Scranton Richard | Chief Scientific Of ... | Grant | A | 0.00 | 7,875 | 0 | 20,101 | 12.2 K to 20.1 K (+64.41 %) |
Jun 08 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 37.53 | 2,600 | 97,578 | 82,040 | 84.6 K to 82 K (-3.07 %) |
Jun 08 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 36.63 | 7,191 | 263,406 | 84,640 | 91.8 K to 84.6 K (-7.83 %) |
Jun 08 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 35.61 | 8,615 | 306,780 | 91,831 | 100.4 K to 91.8 K (-8.58 %) |
Jun 06 2018 | PCRX | Pacira Pharmaceuti ... | Williams Kristen Marie | CAO and General Cou ... | Sell | S | 33.02 | 2,040 | 67,361 | 19,272 | 21.3 K to 19.3 K (-9.57 %) |
Jun 06 2018 | PCRX | Pacira Pharmaceuti ... | Weiland Robert J. | Chief Commercial Of ... | Sell | S | 33.02 | 373 | 12,316 | 5,088 | 5.5 K to 5.1 K (-6.83 %) |
Jun 06 2018 | PCRX | Pacira Pharmaceuti ... | Scranton Richard | Chief Scientific Of ... | Sell | S | 33.02 | 1,367 | 45,138 | 12,226 | 13.6 K to 12.2 K (-10.06 %) |
Jun 06 2018 | PCRX | Pacira Pharmaceuti ... | Riker Lauren Bullaro | Vice President, Fin ... | Sell | S | 33.02 | 801 | 26,449 | 9,641 | 10.4 K to 9.6 K (-7.67 %) |
Jun 06 2018 | PCRX | Pacira Pharmaceuti ... | Reinhart Charles A. III | Chief Financial Off ... | Sell | S | 33.02 | 708 | 23,378 | 8,042 | 8.8 K to 8 K (-8.09 %) |
Jun 06 2018 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 33.90 | 771 | 26,137 | 2,747 | 3.5 K to 2.7 K (-21.92 %) |
May 17 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 10.81 | 10,000 | 108,100 | 13,481 | |
May 17 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Option Exercise | M | 5.49 | 15,000 | 82,350 | 610 | |
May 17 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 34.34 | 3,894 | 133,720 | 100,446 | 104.3 K to 100.4 K (-3.73 %) |
May 17 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Sell | S | 33.69 | 21,106 | 711,061 | 104,340 | 125.4 K to 104.3 K (-16.82 %) |
May 17 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 10.81 | 10,000 | 108,100 | 125,446 | 115.4 K to 125.4 K (+8.66 %) |
May 17 2018 | PCRX | Pacira Pharmaceuti ... | STACK DAVID M | CEO and Chairman | Buy | M | 5.49 | 15,000 | 82,350 | 115,446 | 100.4 K to 115.4 K (+14.93 %) |
May 04 2018 | PCRX | Pacira Pharmaceuti ... | Scranton Richard | Chief Scientific Of ... | Option Exercise | A | 34.38 | 20,000 | 687,500 | 20,000 |